Guardant Health’s Shield™, a pioneering blood test for colorectal cancer screening, has been included in TIME magazine’s 2024 list of the Best Inventions, which recognizes 200 innovations impacting healthcare, AI, and other fields. Shield, which gained FDA approval and Medicare reimbursement earlier in 2024, is celebrated for its ability to detect colorectal cancer at earlier stages, potentially saving lives by offering a less invasive, accessible screening option. The selection highlights Guardant’s commitment to transforming cancer diagnostics, as the company reaches milestones of 500 peer-reviewed publications and over 500,000 patient tests. Guardant co-CEO AmirAli Talasaz noted the honor as a testament to Shield’s potential to transform cancer detection.
Guardant Health Named to TIME’s List of the Best Inventions of 2024 (Guardant Health)
0